Senolytics, targeting aging cells causing inflammation, are emerging as the next frontier in longevity supplements, following the success of NAD+ products.
The global longevity supplement market has grown from a niche interest into a multi-billion dollar industry. What was once limited to basic multivitamins and omega-3 capsules has expanded into a sophisticated landscape of targeted compounds, each designed to address specific biological mechanisms of aging.
The first category to break through was NAD+. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) became the flagship molecules of the consumer longevity movement, driven by published research linking NAD+ decline to mitochondrial dysfunction — one of the twelve recognized hallmarks of aging. For many consumers, NAD+ supplements were the first product that connected the language of aging biology with something they could actually buy.
But NAD+ decline is one hallmark out of twelve. And as the market matures, attention is shifting to what comes next.
The category that science built
Cellular senescence — the accumulation of dysfunctional zombie cells that resist normal cell death and drive chronic inflammation — has emerged as one of the most actively researched hallmarks of aging. Over the past decade, institutions including Mayo Clinic, MIT and the University of Texas Health Science Center have published extensively on how senescent cells contribute to age-related decline across tissues and organs.
The compounds that target these cells are called senolytics. A landmark 2018 study in EBioMedicine screened ten naturally occurring flavonoids for senolytic activity, with fisetin and quercetin emerging among the most promising. Clinical trials are now underway, and the research base is growing rapidly.
Yet despite a body of scientific literature comparable to NAD+, consumer senolytics barely exists as a product category. The gap between research interest and market presence is striking — and it’s beginning to close.
A different kind of supplement
The slow commercial development of senolytics has a structural explanation. NAD+ supplements fit the traditional supplement model perfectly: a daily capsule, a monthly bottle, a recurring subscription. The consumer behavior is familiar and the retail model is proven.
Senolytics don’t work that way. The dominant approach in clinical research uses intermittent dosing — short, concentrated interventions of two to three days, followed by weeks of rest. This is grounded in how senolytic compounds appear to function: triggering apoptosis in senescent cells during brief exposure windows, then allowing the body’s natural repair systems to do the rest.
For supplement companies, this creates a product design challenge. An intermittent protocol means fewer units sold per month, a different subscription cadence, and a consumer education hurdle. It’s a harder category to build a business around — which partly explains why so few have tried.
Two hallmarks, one company
Swedish longevity company Lifeseeds is one of the few companies currently operating across both categories. Their NAD+ supplement, Nexus, targets mitochondrial function and cellular energy. Their recently launched senolytic supplement, Zenith, combines high-dose fisetin (1,400 mg) and quercetin (500 mg) in an intermittent two-day monthly protocol designed to mirror clinical senolytic research.
Together, the two products address two distinct hallmarks of aging — NAD+ decline and cellular senescence — within a single product range. It’s an approach that reflects the direction of the science itself: moving away from broad-spectrum formulas toward targeted interventions built around specific biological mechanisms.
“The hallmarks framework changed how we think about product development,” says Mathias Lobendahl, founder of Lifeseeds. “Instead of making one supplement that tries to do everything, we build each product around a specific mechanism of aging. NAD+ decline and cellular senescence are two of the most well-researched hallmarks — and they require completely different approaches. Nexus is taken daily. Zenith is taken two days a month. Biology dictates the protocol, not the business model.”
The second wave
Whether senolytics replicate the commercial trajectory of NAD+ is an open question. The science is still maturing, and the category faces the inherent challenge of translating preclinical research into consumer confidence. But the structural parallels are hard to ignore: a well-defined biological mechanism, a growing body of published research, clinical trials at major institutions, and a clear gap between scientific interest and market availability.
The first wave of longevity supplements was built around a single hallmark of aging. The second wave may be defined by how many hallmarks a company can credibly address — and by whether consumers are ready for products that work differently from anything they’ve taken before.
Sources: López-Otín et al., “Hallmarks of Aging: An Expanding Universe,” Cell, 2023. Zhu et al., “New agents that target senescent cells,” EBioMedicine, 2018. Kirkland & Tchkonia, Mayo Clinic, 2017.
